854 related articles for article (PubMed ID: 12198643)
21. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
22. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
[TBL] [Abstract][Full Text] [Related]
23. [Treatment of cholestatic liver diseases; the role of ursodeoxycholic acid].
Stiehl A
Z Gastroenterol; 1992 Oct; 30(10):743-7. PubMed ID: 1441678
[TBL] [Abstract][Full Text] [Related]
24. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
Lebensztejn DM
Med Sci Monit; 2000; 6(3):632-6. PubMed ID: 11208384
[TBL] [Abstract][Full Text] [Related]
25. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis.
Macias RI; Serrano MA; Monte MJ; Jimenez S; Hernandez B; Marin JJ
J Pharmacol Exp Ther; 2005 Feb; 312(2):751-8. PubMed ID: 15452192
[TBL] [Abstract][Full Text] [Related]
26. Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis.
Razori MV; Maidagan PM; Ciriaci N; Andermatten RB; Barosso IR; Martín PL; Basiglio CL; Sánchez Pozzi EJ; Ruiz ML; Roma MG
Biochem Pharmacol; 2019 Oct; 168():48-56. PubMed ID: 31202734
[TBL] [Abstract][Full Text] [Related]
27. Pathogenesis of cholestatic liver disease and therapeutic approaches.
Hirschfield GM; Heathcote EJ; Gershwin ME
Gastroenterology; 2010 Nov; 139(5):1481-96. PubMed ID: 20849855
[TBL] [Abstract][Full Text] [Related]
28. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
[TBL] [Abstract][Full Text] [Related]
29. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid.
Perez MJ; Macias RI; Duran C; Monte MJ; Gonzalez-Buitrago JM; Marin JJ
J Hepatol; 2005 Aug; 43(2):324-32. PubMed ID: 15970352
[TBL] [Abstract][Full Text] [Related]
30. Ursodeoxycholic acid in the treatment of chronic liver disease.
Cirillo NW; Zwas FR
Am J Gastroenterol; 1994 Sep; 89(9):1447-52. PubMed ID: 8079918
[TBL] [Abstract][Full Text] [Related]
31. Choleretic effects of ursodeoxycholic acid on experimentally-induced intrahepatic cholestasis.
Mizoguchi Y; Miyajima K; Kioka K; Seki S; Kobayashi K; Morisawa S
Osaka City Med J; 1989 Nov; 35(2):83-91. PubMed ID: 2628845
[TBL] [Abstract][Full Text] [Related]
32. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.
Silveira MG; Lindor KD
Clin Liver Dis; 2008 May; 12(2):425-43; x-xi. PubMed ID: 18456189
[TBL] [Abstract][Full Text] [Related]
33. Pharmacotherapy of cholestatic liver diseases.
Paumgartner G
J Dig Dis; 2010 Jun; 11(3):119-25. PubMed ID: 20579215
[TBL] [Abstract][Full Text] [Related]
34. Ursodeoxycholic acid therapy in hepatobiliary disease.
Kowdley KV
Am J Med; 2000 Apr; 108(6):481-6. PubMed ID: 10781781
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of cholestatic liver diseases].
Gatzen M; Pausch J
Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
[TBL] [Abstract][Full Text] [Related]
36. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
Linares Rodríguez A
Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
[No Abstract] [Full Text] [Related]
37. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
38. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress.
Serviddio G; Pereda J; Pallardó FV; Carretero J; Borras C; Cutrin J; Vendemiale G; Poli G; Viña J; Sastre J
Hepatology; 2004 Mar; 39(3):711-20. PubMed ID: 14999689
[TBL] [Abstract][Full Text] [Related]
39. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection.
Botla R; Spivey JR; Aguilar H; Bronk SF; Gores GJ
J Pharmacol Exp Ther; 1995 Feb; 272(2):930-8. PubMed ID: 7853211
[TBL] [Abstract][Full Text] [Related]
40. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.
Arenas F; Hervias I; Uriz M; Joplin R; Prieto J; Medina JF
J Clin Invest; 2008 Feb; 118(2):695-709. PubMed ID: 18188457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]